| +0.38 / +3.46%|
Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Its product candidate, dalbavancin, is in late stage clinical development. The company is initially developing dalbavancin, an intravenous antibiotic product candidate, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI, caused by Gram-positive bacteria, such as S. aureus, including Methicillin-Resistant and multi-drug resistant strains, and certain Streptococcal species. Dalbavancin is a second generation, semi-synthetic lipoglycopeptide designed for once-weekly intravenous dosing which will facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, reducing the length of a patient's hospital stay or avoiding hospital admission altogether and, ultimately, lowering the overall cost of care for these patients. The company was founded on November 4, 2009 and is headquartered in Chicago, IL.
|Paul R. Edick||President, Chief Executive Officer & Director|
|Corey N. Fishman||COO, CFO, Secretary & Treasurer|
|Michael W. Dunne||Chief Medical Officer|
|John Patrick Shannon||Chief Commercial Officer|
|Allison Wey||Vice President-Investor Relations & Public Affairs|